Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum

NCT04274166 is registered in ClinicalTrials.gov with Wake Forest University Health Sciences as lead sponsor.

NCT NCT04274166
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04274166 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum
Lead sponsor
Wake Forest University Health Sciences
Phase
Phase 2
Overall status
Withdrawn
Start date
May 31, 2021
Completion date
April 30, 2022
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pyoderma gangrenosum